Mangoceuticals (MGRX) shares dropped after hours despite its former subsidiary, MangoRx IP Holdings, securing a $2.5 million strategic investment. The market reaction suggests investor concern over the structure of the deal, which dilutes ownership at the subsidiary level without directly benefiting MGRX's balance sheet or share count, or perhaps a 'sell the news' event.
Mangoceuticals (MGRX) saw its shares fall 12% after hours, even though its former subsidiary, MangoRx IP Holdings, secured a $2.5 million strategic investment. This investment, structured at the subsidiary level, means Mangoceuticals itself did not issue new shares or directly receive the capital, though it does validate the subsidiary's value. The negative market reaction could stem from investors perceiving this as a less direct benefit to the parent company, or perhaps a 'sell the news' event following the announcement. While the CEO framed it positively as non-dilutive to MGRX common stock, the market's immediate response indicates skepticism or a lack of clear positive catalysts for the parent company's valuation, especially given its already significant share price decline over the past year.